Urology
The urinary system is affected by many factors such as aging, infection, injury, and underlying illnesses. These factors can lead to a wide range of disorders that cause painful, life-disrupting symptoms. Ferring is committed to helping people treat and overcome these disorders and restoring their quality of life.
The Ferring Group has long been involved in the research and development of products that treat urologic disorders. For example, desmopressin acetate, an analog of the human anti-diuretic hormone vasopressin, was originally discovered by The Ferring Group.
The introduction of Prosed® DS for urinary pain and discomfort marks our first
US-branded entry into this therapeutic category. A number of additional products, however, are currently in clinical trials. Our goal is to further help patients by improving and expanding upon our existing urology portfolio through continued development and acquisition.
For more information on Prosed® DS, please click here.
Firmagon (Degarelix for Injection)
On December 24, 2008, Ferring Pharmaceuticals received approval from the U.S. Food and Drug Administration (FDA) for Firmagon (Degarelix for Injection), a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer.
For more information on Firmagon (Degarelix for Injection), please click here.
